Histone Deacetylase Inhibitors and Bladder Cancer

Journal of Urology

Volumn 183, Issue 6, 2010, Pages 2120-2121

  Adam, Rosalyn M ^a  

^a BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 N ACETYLDINALINE; ADENOVIRUS VECTOR; ALPHA CATENIN; BELINOSTAT; CARBOPLATIN; COXSACKIE VIRUS AND ADENOVIRUS RECEPTOR; CYCLIN DEPENDENT KINASE INHIBITOR 1; CYCLIN DEPENDENT KINASE INHIBITOR 1B; CYCLIN DEPENDENT KINASE INHIBITOR 2A; DESMOGLEIN; FOCAL ADHESION KINASE; HISTONE ACETYLTRANSFERASE; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; PLAKOGLOBIN; TRICHOSTATIN A; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; VALPROIC ACID; VORINOSTAT;

ACETYLATION; AGING; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BLADDER CANCER; CANCER CELL; CANCER RISK; CELL CYCLE ARREST; CELL DIFFERENTIATION; CLINICAL TRIAL; DNA METHYLATION; DNA TRANSCRIPTION; DOWN REGULATION; DRUG EFFICACY; DRUG TARGETING; DRUG TOLERABILITY; EDITORIAL; EPIGENETICS; GENE EXPRESSION; HUMAN; INCIDENCE; PRIORITY JOURNAL; RISK FACTOR; SMOKING; UPREGULATION;

HISTONE DEACETYLASE INHIBITORS; HUMANS; URINARY BLADDER NEOPLASMS;

EID: 77951880821     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.juro.2010.03.047     Document Type: Editorial

References (10)

1. Horner M.J., Ries L.A.G., Krapcho M., et al. SEER Cancer Statistics Review, 1975-2006 (2008), National Cancer Institute, Bethesda
2. Lane A.A., and Chabner B.A. Histone deacetylase inhibitors in cancer therapy. J Clin Oncol 27 (2009) 5459
3. Carew J.S., Giles F.J., and Nawrocki S.T. Histone deacetylase inhibitors: mechanisms of cell death and promise in combination cancer therapy. Cancer Lett 269 (2008) 7
4. Canes D., Chiang G.J., Billmeyer B.R., et al. Histone deacetylase inhibitors upregulate plakoglobin expression in bladder carcinoma cells and display antineoplastic activity in vitro and in vivo. Int J Cancer 113 (2005) 841
5. Rieger-Christ K.M., Ng L., Hanley R.S., et al. Restoration of plakoglobin expression in bladder carcinoma cell lines suppresses cell migration and tumorigenic potential. Br J Cancer 92 (2005) 2153
6. Buckley M.T., Yoon J., Yee H., et al. The histone deacetylase inhibitor belinostat (PXD101) suppresses bladder cancer cell growth in vitro and in vivo. J Transl Med 5 (2007) 49
7. El-Zawahry A., Lu P., White S.J., et al. In vitro efficacy of AdTRAIL gene therapy of bladder cancer is enhanced by trichostatin A-mediated restoration of CAR expression and downregulation of cFLIP and Bcl-XL. Cancer Gene Ther 13 (2006) 281
8. Kelly W.K., Richon V.M., O'Connor O., et al. Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously. Clin Cancer Res 9 (2003) 3578
9. Kelly W.K., O'Connor O.A., Krug L.M., et al. Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. J Clin Oncol 23 (2005) 3923
10. Pauer L.R., Olivares J., Cunningham C., et al. Phase I study of oral CI-994 in combination with carboplatin and paclitaxel in the treatment of patients with advanced solid tumors. Cancer Invest 22 (2004) 886